Production (Stage)
Skye Bioscience, Inc.
SKYE
$1.99
-$0.21-9.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -32.65M | -26.57M | -21.24M | -42.29M | -37.50M |
| Total Depreciation and Amortization | 448.50K | 298.70K | 151.80K | 114.60K | 118.70K |
| Total Amortization of Deferred Charges | 361.80K | 599.00K | 826.50K | 817.40K | 567.10K |
| Total Other Non-Cash Items | 3.93M | 3.06M | 1.22M | 25.20M | 23.25M |
| Change in Net Operating Assets | -1.80M | -2.63M | -1.87M | -3.55M | -1.04M |
| Cash from Operations | -29.71M | -25.24M | -20.91M | -19.70M | -14.60M |
| Capital Expenditure | -1.61M | -1.60M | -1.56M | -46.40K | -13.90K |
| Sale of Property, Plant, and Equipment | 213.20K | 1.36M | 1.22M | 1.15M | 1.15M |
| Cash Acquisitions | -- | -- | 0.00 | 1.08M | 1.08M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -12.80M | -- | -- | -- | -- |
| Cash from Investing | -14.20M | -245.60K | -343.00K | 2.18M | 2.21M |
| Total Debt Issued | -- | -- | 0.00 | 4.97M | 4.97M |
| Total Debt Repaid | -- | -- | -22.70K | -90.70K | -214.10K |
| Issuance of Common Stock | 6.44M | 92.09M | 85.92M | 97.65M | 97.65M |
| Repurchase of Common Stock | -2.10M | -2.10M | -2.10M | -2.10M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.43M | -6.43M | -265.10K | -271.10K | -271.10K |
| Cash from Financing | -2.09M | 83.56M | 83.53M | 100.17M | 102.14M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -46.00M | 58.08M | 62.28M | 82.64M | 89.75M |